Healthcare Global Enterprises Limited, one of the largest providers of cancer care in India under the brand HCG has reported Q3 FY23 revenues of Rs. 424.7 crore, up 19% YoY and profit after tax of Rs. 7.5 crore.
Commenting on the results, Dr. B. S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “At HCG, we strive to provide the best-in-class treatments for our patients across the value chain. We have been focusing on consistently upgrading our skill set with the deep domain knowledge, upgradation of technology & urge to treat cancer for the best possible outcomes for every single patient under the HCG horizon. Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations. It is the intelligent deployment of technology that serves the larger cause of healthcare."
"At HCG, patient care is approached holistically based on risk and severity of disease - from pre-admission to post-discharge – and is aimed at enhancing outcomes, lowering costs, and better resource management. Whether Linac technology, Teleradiology, Bioinformatics, Genomics, Robotic surgery, Digital pathology, or Adaptive AI, HCG's technology adoption is unflinchingly focused on patient outcomes. Our focus has been on Oncology in conjunction with local partners, and has helped us build a strong legacy as a World-class Oncology Treatment Center & Institution across India,” commented Ajaikumar.
Raj Gore, CEO HealthCare Global Enterprises Ltd. said, “I am extremely happy to share that we have once again outgrown the industry growth and our revenues for Q3FY23 grew by 19% on Y-o-Y basis to Rs. 4,247 mn. With accelerated awareness in the society for Cancer care & diagnosis and HCG, being a trusted brand in the medical fraternity for Cancer care, we expect the revenue growth to improve and margins to enhance due to operating leverage play. We have seen growth in our volumes & patient count across modalities and with increased awareness, investments in digital technology, marketing initiatives & positive outcomes, we are optimistic of sustaining the growth momentum.""
At HCG, we believe in patient centric care, focus on accessible oncological services, advanced treatments and high-quality care & outcomes. Over the years we have emerged as a responsible brand earning the trust of thousands of patients and admiration of the community which has led us to be the leader in most of the markets we are present in. Going forward, we continue to invest in the HCG brand and penetrate deeper into the markets of our core geography and attain leadership positions in newer territories through superior treatment & outcomes,” added Gore.
